Medical/Pharmaceuticals

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...

2024-07-26 23:21 1710

MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...

2024-07-26 21:02 1937

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Europ...

2024-07-26 20:16 2140

MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports

PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports a...

2024-07-26 19:35 1159

Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View

PORT VILA, Vanuatu, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker,  Vantage Markets

2024-07-26 17:05 900

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

SYDNEY, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 1711

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-07-26 09:33 1561

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

SINGAPORE, July 25, 2024 /PRNewswire/ -- ObvioHealth , a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research an...

2024-07-25 16:39 1678

Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot

Uplifting pharmacists' role in primary care and positioning pharmacies as  essential care destinations in local communities  CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ -- MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software tra...

2024-07-25 05:00 1583

SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study

SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US,Europe and Israel TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie , which has developed a novel proprietary Therapeutic Intra-Vascular Ultras...

2024-07-24 20:09 1084

Corero Network Security Announces H1 Financial Results

Company posts 16% YoY growth with increases in ARR and bookings LONDON, July 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced its financial results for the first half of 2024. The company ...

2024-07-24 19:00 1950

deCODE genetics: Variants in the genome affect DNA methylation

REYKJAVIK, Iceland, July 24, 2024 /PRNewswire/ -- A new study by scientists at deCODE Genetics, subsidiary of Amgen, shows that sequence variants drive the correlation between DNA methylation and gene expression. The same variants are linked to various diseases as well as other human traits.   ...

2024-07-24 17:00 1157

For the First time in Thailand! Chulalongkorn University Researchers Found a "Glowing Land Snail"

BANGKOK, July 24, 2024 /PRNewswire/ -- Chulalongkorn University researchers have discovered Thailand's first glowing land snail  and the first one in the world in the last 80 years.  Preparations are underway to decode it...

2024-07-24 16:46 1762

Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services

Aragen Life Sciences Ltd. excels in providing end-to-end drug discovery and development solutions, showcasing its innovative approaches and strong commitment to sustainability and customer satisfaction. SAN ANTONIO, July 24, 2024 /PRNewswire/ -- Frost & Sullivan has recognized Aragen Life Scienc...

2024-07-24 12:30 1185

FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, July 24, 2024  /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...

2024-07-24 08:10 1332

Telix Successfully Prices A$650 Million Convertible Bonds

MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...

2024-07-24 07:51 1210

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling universal, language-free usage for fast and accurate results. SAN ANTONIO, July 23, 2024 /PRNewswire/ -- Frost & Sullivan recently analyzed the brain, m...

2024-07-23 21:00 1258

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...

2024-07-23 16:35 1394

SND Introduces Revolutionary Moderated Drinking Treatment Program

TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...

2024-07-23 16:29 1325

Linical Named Best Global CRO by Global Health & Pharma Magazine

OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title ofBest Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence A...

2024-07-23 09:00 1664
12345 ... 389

Week's Top Stories